INVESTIGADORES
LANUSSE Carlos Edmundo
artículos
Título:
Identification of a field isolate of Fasciola hepatica resistant to albendazole and susceptible to triclabendazole.
Autor/es:
SANABRIA, R; CEBALLOS, L; MORENO, L; ROMERO, J; LANUSSE, C; ALVAREZ, L
Revista:
VETERINARY PARASITOLOGY
Editorial:
ELSEVIER SCIENCE BV
Referencias:
Lugar: Amsterdam; Año: 2013 p. 105 - 110
ISSN:
0304-4017
Resumen:
The experiments described here were designed to characterize the status of susceptibility/
resistance to albendazole (ABZ) and triclabendazole (TCBZ) of a Fasciola hepatica
isolate (named CEDIVE isolate) recovered from infected sheep (Gualeguay, Argentina) and
maintained under laboratory conditions. Two separate clinical efficacy experiments were
performed on sheep artificially infected with the CEDIVE isolate. Experiment 1: sheep were
randomly distributed either in an untreated control group or in an ABZ (7.5 mg/kg) treated
group (n = 4 each). Additionally, the systemic exposure of ABZ metabolites was assessed
in those ABZ-treated infected animals. In Experiment 2, an untreated control group and a
TCBZ (10 mg/kg) treated group was included (n = 4 each). The fluckicidal efficacy of ABZ and
TCBZ was assessed by the comparison of the number of flukes recovered from untreated
and treated sheep at 15 days post-treatment. The efficacy against the CEDIVE isolate of F.
hepatica was 29% (ABZ) and 100% (TCBZ). The plasma drug exposure (expressed as AUC
and Cmax) observed in the ABZ treated animals (Experiment 1) was in agreement with data
obtained in the previous studies, which indicate that the low ABZ efficacy was not related
to the quality of the pharmaceutical product and/or to a low systemic availability of the
active drug/metabolite. The results reported here clearly show that the CEDIVE isolate of F.
hepatica behaves as resistant to ABZ and susceptible to TCBZ.